Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

Autor: Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang, Xin Li, Jing Chen, Xianmin Song, Hongmei Jing, Yuhua Li, Siguo Hao, Wenjun Wu, Yamin Tan, Jian Yu, Yanmin Zhao, Xiaoyu Lai, Elaine Tan Su Yin, Yunxiong Wei, Ping Li, Jing Huang, Tao Wang, Didier Blaise, Lei Xiao, Alex H. Chang, Arnon Nagler, Mohamad Mohty, He Huang, Yongxian Hu

Publikováno v: Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)

Abstract Background Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T cell (CAR-T) therapy. We performed a m

Externí odkaz: https://doaj.org/article/0d9754ba37f949e9a37c2ca215e508a1

Characterization and prognostic implication of delayed complete response in AL amyloidosis

Autor: Morie A. Gertz, Eli Muchtar, Shaji Kumar, Rahma Warsame, Suzanne R. Hayman, Miriam Hobbs, Angela Dispenzieri, S. Vincent Rajkumar, Wilson I. Gonsalves, Martha Q. Lacy, Amie Fonder, Stephen J. Russell, Francis K. Buadi, Robert A. Kyle, John A. Lust, David Dingli, Nelson Leung, Mustaqueem Siddiqui, Yi Lisa Hwa, Prashant Kapoor, Taxiarchis Kourelis, Ronald S. Go

Publikováno v: Eur J Haematol

INTRODUCTION: Little is known on continued response following completion of therapy in light chain (AL) amyloidosis. METHODS: We studied 373 AL amyloidosis patients who achieved complete response (CR) or very good partial response (VGPR) to first-lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56000c03db0ed7ce0fc3bea1fd2b60e1
https://doi.org/10.1111/ejh.13554

New approaches to the treatment of older adults with acute lymphoblastic leukemia

Autor: Marc S. Schwartz, Matthew J. Wieduwilt

Publikováno v: Seminars in Hematology. 57:122-129

Outcomes for older adults (defined here as ≥55-65 years old) with acute lymphoblastic leukemia (ALL) are poor, with long-term survival less than 20%. Pediatric chemotherapy regimens produce long-term cure rates of 80% to 90% in children and 60% to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12029946d5cc115c7939242a64c168d7
https://doi.org/10.1053/j.seminhematol.2020.09.001

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

Autor: Werner J. Heinz, Sebastian Böttcher, Petra Langerbeins, Othman Al-Sawaf, Stephanie Sasse, Barbara Eichhorst, Michael Hallek, Anna-Maria Fink, Eugen Tausch, Jan Dürig, Manfred Hensel, Kirsten Fischer, Sandra Robrecht, Matthias Ritgen, Paula Cramer, Jasmin Bahlo, Michael Kneba, Karl-Anton Kreuzer, Moritz Fürstenau, Clemens-Martin Wendtner, Julia von Tresckow, Stephan Stilgenbauer, Natali Pflug, Ursula Vehling-Kaiser

Publikováno v: Haematologica

Background: The introduction of targeted agents has revolutionized the treatment of CLL but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. Methods: This multicentre, investigator-init

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d832e5cccc149ebdae3d3e9b7b905b06
https://doi.org/10.3324/haematol.2019.223693

Prognostic value of minimal residual disease negativity in myeloma:combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Autor: Hervé Avet-Loiseau, Steven Sun, Torben Plesner, Andrew Spencer, Aurore Perrot, Thierry Facon, Rachel Kobos, Philippe Moreau, Saad Z. Usmani, Meletios A. Dimopoulos, Shinsuke Iida, Jianping Wang, Maria Krevvata, Niels W.C.J. van de Donk, Vania Hungria, Maria-Victoria Mateos, Katja Weisel, Bruno Paiva, Nizar J. Bahlis, Michele Cavo, Christoph Heuck, Nikhil C. Munshi, Jesús F. San-Miguel, Shaji Kumar, M. Qi, Pieter Sonneveld, Jon Ukropec

Publikováno v: Cavo, M, San-Miguel, J, Usmani, S Z, Weisel, K, Dimopoulos, M A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V, Moreau, P, Mateos, M-V, Perrot, A, Iida, S, Facon, T, Kumar, S, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
Blood, 139(6), 835-844. American Society of Hematology
Cavo, M, San-Miguel, J F F, Usmani, S Z, Weisel, K C, Dimopoulos, M A A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V T D M, Moreau, P, Mateos, M V, Perrot, A, Iida, S, Facon, T, Kumar, S K, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N C 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c64997dd452605ab785f5859d6df78
https://research.vumc.nl/en/publications/4fe089e5-72a4-42e8-a3c4-bb08bb52d9fe